| ST060266 Order online | ST078925 Order online | ST045849 Order online |
|
|
|
|
| MW: 289.67
phenyl 5-chloro-2-oxo-3-hydrobenzoxazole-3-carboxylate
|
MW: 406.53 4-[(3-cyano-4-(2-thienyl)-2-5,6,7,8-tetrahydroquinolylthio)methyl]benzoic acid ST078925 analog-substitute to validated inhibitor #6, Figure 3. of the paper
|
MW: 447.00 3-(2-adamantanylethyl)-2-[(4-chlorophenyl)azamethylene]-4-oxo-1,3-thiazaperhyd roine-6-carboxylic acid OGT inhibitor, ST045849, TT04,treatment reduces beta-cell development: |
 |
|
|
Compounds with proven activity are available from stock.
TimTec assembled small targeted compound collection of over 300 compounds-analogs based on three validated O-GlcNAc Transferase inhibitors (following the results of the discovery at Department of Microbiology and Molecular Genetics, HUMS)
Reference:
Gross, B.J, Kraybill, B.C., Walker, S. Discovery of O-GlcNAc Transferase Inhibitors. Department of Microbiology and Molecular Genetics, Harvard Medical School. JACS Communications, published on Web 09/29/05; J. Am. Chem. Soc. 2005, 127, 14588-14589.
Filhoulaud, G., et al. The hexosamine biosynthesis pathway is essential for pancreatic beta cell development. J Biol Chem. 2009 Sep 4;284(36):24583-94.
Discovery of O-GlcNAc Transferase Inhibitors Harvard Medical School
